Zhuoling An

Capital Medical University

H指数:18

被引数:1,215

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Integrative characterization of Huachansu against hepatocellular carcinoma: chemical profiling; Network pharmacology; and in vivo evidence of apoptosis and gut microbiota remodeling

华蟾素抗肝细胞癌的整合表征：化学分析；网络药理学；以及体内凋亡和肠道菌群重塑的证据

Frontiers in Chemistry

IF4.2

2026-05-130

OAAI

Plasma metabolomics disentangles T2DM- and CAD-specific dysmetabolism and identifies potential biomarkers for CAD risk escalation in diabetic patients

血浆代谢组学解析了T2DM和CAD特异性的代谢紊乱，并鉴定了糖尿病患者的CAD风险增加的潜在生物标志物

Cardiovascular Diabetology

IF10.6

2025-11-220

OAAI

Lipidomic machine learning predictor for progression of gastric cancer

脂质组学机器学习预测器在胃癌进展中的应用

Clinica Chimica Acta

IF2.9

2025-11-200

PRE

Metabolic heterogeneity, networks, and biomarkers of drug-induced liver injury

药物诱导性肝损伤的代谢异质性、网络和生物标志物

Journal of Pharmaceutical Analysis

IF8.9

2025-11-130

OAAI

Efficacy and Safety of Simnotrelvir-Ritonavir Compared With Nirmatrelvir-Ritonavir in the Treatment of COVID-19: Real-World Evidence From a Retrospective Cohort Study During the Prevalence of the Omicron EG.5 Variant

沙莫特雷韦-利托那韦与奈玛特雷韦-利托那韦治疗COVID-19的疗效与安全性比较：奥密克戎EG.5变异株流行期间一项回顾性队列研究的真实世界证据

Clinical Therapeutics

IF3.6

2025-07-030

PRE

Thromboembolic and bleeding events associated with angiogenesis inhibitors in cancer patients

癌症患者使用血管生成抑制剂相关的血栓栓塞事件和出血事件

EXPERT OPINION ON DRUG SAFETY

IF3.1

2025-05-210

PRE

Thrombotic Microangiopathy Associated with Calcineurin Inhibitors: A Real-World Analysis of Postmarketing Surveillance Data

CLINICAL THERAPEUTICS

IF3.6

2025-02-010

PRE

Inappropriate Prescribing of Nirmatrelvir/Ritonavir in Solid Organ Transplantation With COVID-19 Infection: A Multicenter Retrospective Study

CLINICAL THERAPEUTICS

IF3.6

2025-01-010

PRE

Paired comparisons of venetoclax concentration in cerebrospinal fluid, bone marrow, and plasma in acute leukemia patients

CTS-CLINICAL AND TRANSLATIONAL SCIENCE

IF2.8

2024-09-171

OAAI

Cost-effectiveness of Azvudine for High-risk Outpatients with Mild-to-moderate Coronavirus Disease 2019 in China

CLINICAL THERAPEUTICS

IF3.6

2024-09-012

PRE

与他克莫司相关的紧张症: FDA不良事件报告系统 (FAERS) 数据库的真实世界药物警戒研究

EXPERT OPINION ON DRUG SAFETY

IF3.1

2024-08-210

PRE

EXPERT OPINION ON DRUG SAFETY

IF3.1

2024-08-190

PRE

CLINICAL THERAPEUTICS

IF3.6

2024-07-010

PRE

Booster vaccines dose reduced mortality in hospitalized COVID-19 patients requiring oxygen supplementation: Evidence from the Beijing Omicron outbreak

HUMAN VACCINES & IMMUNOTHERAPEUTICS

IF3.5

2024-06-212

OAAI

Comparison of four criteria for potentially inappropriate medications in older patients with newly diagnosed non-small cell lung cancer

EXPERT OPINION ON DRUG SAFETY

IF3.1

2024-05-220

PRE

Adherence and recommended optimal treatment to Azvudine application for the treatment of outpatient COVID-19 patients: A real-world retrospective study

坚持和推荐的最佳治疗，以阿兹夫定应用治疗门诊新型冠状病毒肺炎患者: 一个真实世界的回顾性研究

HELIYON

IF3.6

2024-05-011

OAAI

Gamma-aminobutyric acid supplementation improves olanzapine-induced insulin resistance by inhibiting macrophage infiltration in mice subcutaneous adipose tissue

DIABETES OBESITY & METABOLISM

IF5.7

2024-04-251

PRE

Immune checkpoint inhibitor related myositis: an observational, retrospective, pharmacovigilance study

EXPERT OPINION ON DRUG SAFETY

IF3.1

2024-04-242

PRE

Effectiveness and safety of nirmatrelvir-ritonavir in kidney transplant recipients with severe kidney dysfunction infected with COVID-19

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2024-03-062

Machine learning reveals serum myristic acid, palmitic acid and heptanoylcarnitine as biomarkers of coronary artery disease risk in patients with type 2 diabetes mellitus

CLINICA CHIMICA ACTA

IF2.9

2024-03-012

PRE

Zhuoling An

个人简介

教育背景

工作经历

荣誉奖项

研究方向